SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors

Area of Science:

• Oncology
• Medicinal Chemistry
• Biochemistry

Background:

• Histone deacetylase (HDAC) dysregulation is implicated in carcinogenesis, making HDAC inhibitors a key target in cancer therapy.
• Hydroxamic acid derivatives, such as suberoylanilide hydroxamic acid (SAHA), represent a broad class of HDAC inhibitors currently used in clinical trials.
• The development of novel HDAC inhibitors with improved efficacy and potentially different mechanisms of action is an ongoing area of research.

Purpose of the Study:

• To synthesize and evaluate novel selenium-containing compounds as potential HDAC inhibitors.
• To compare the HDAC inhibitory activity of these new compounds against the established inhibitor SAHA.
• To explore the potential of selenium-based molecules in cancer therapy.

Main Methods:

• Synthesis of two selenium-containing compounds, SelSA-1 and SelSA-2, modeled after SAHA.
• In vitro assessment of HDAC inhibitory activity for both SelSA-1 and SelSA-2.
• Determination of IC50 values to quantify the potency of the synthesized compounds and compare them to SAHA.

Main Results:

• Both synthesized selenium compounds, SelSA-1 and SelSA-2, demonstrated potent HDAC inhibitory activity.
• SelSA-2 exhibited significantly higher potency, with an IC50 value of 8.9 nM, compared to SAHA's IC50 value of 196 nM.
• These results highlight the potential of selenium incorporation into HDAC inhibitor design.

Conclusions:

• Novel selenium-containing compounds, SelSA-1 and SelSA-2, are potent inhibitors of HDAC.
• SelSA-2 represents a highly potent HDAC inhibitor, surpassing the efficacy of SAHA in preliminary evaluations.
• This study introduces a promising new avenue for developing selenium-based HDAC inhibitors for cancer treatment.